Ascendis 与 BioMarin 宣布，双方已正式签署一份具有约束力的条款清单，旨在于全球范围内就 Yuviwel®（Navepegritide）相关事宜达成全面和解与许可安排。此举标志着两家公司围绕该产品展开的长期纠纷或合作谈判进入关键性的实质性阶段，为后续正式协议的最终落地奠定了坚实基础。
Ascendis 与 BioMarin 宣布，双方已正式签署一份具有约束力的条款清单，旨在于全球范围内就 Yuviwel®（Navepegritide）相关事宜达成全面和解与许可安排。此举标志着两家公司围绕该产品展开的长期纠纷或合作谈判进入关键性的实质性阶段，为后续正式协议的最终落地奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.